TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  Benzinga

Novartis' Investigational Drug Reports Longer Disease Control In Patients With Rare Blood Disorder

Benzinga Logo Benzinga By Vandana Singh
Novartis' Investigational Drug Reports Longer Disease Control In Patients With Rare Blood Disorder

Novartis reported positive Phase 3 trial results for ianalumab plus eltrombopag in treating primary immune thrombocytopenia (ITP), showing extended disease control and improved platelet count in patients previously treated with corticosteroids.

Insights
NVS   positive

Demonstrated significant clinical trial success with extended disease control (45% longer time to treatment failure), higher sustained platelet count improvement, and potential for expanded treatment applications in B-cell-driven autoimmune diseases